A trial looking at apitolisib with everolimus for kidney cancer that has spread (ROVER)
Cancer type:
Status:
Phase:
This trial compared apitolisib and everolimus for kidney cancer that had spread to another part of the body. It was for people with renal cell cancer (RCC).
The trial was open for people to join between 2011 and 2012. The team published the results in 2016.
More about this trial
Renal cell cancer is the most common type of kidney cancer in adults.
When this trial was done, doctors sometimes used everolimus to treat advanced renal cell cancer. Everolimus is a type of targeted treatment called a cancer growth blocker. It stops the signals that cancer cells need to divide and grow.
Apitolisib (GDC-0980) is also a type of cancer growth blocker. It works in a slightly different way to everolimus. Researchers hoped that apitolisib may be better than everolimus to treat kidney cancer that has spread.
People in this trial were put into a treatment group at random:
- half had everolimus
- half had apitolisib
The main aim of the trial was to find out if apitolisib is better than everolimus for kidney cancer that has spread.
Summary of results
As part of our editorial policy, any trial information we write is checked externally before we put it on our website. The research team have published some results for this trial. But we have been unable to find anyone involved with the trial to check the summary for us.
This means we are not able to include a plain English summary of the results on this page.
More information
There is more information about this trial in the link to the medical journal below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
T Powles and others
Journal of Clinical Oncology (2016). Volume 34, issue 14, pages 1660 – 1668.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Thomas Powles
Supported by
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Roche-Genentech
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
